The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
Poll|Poll|January 11, 2024
POLL: Are You Attending the 2024 Winter Clinical Dermatology Conference in Hawaii?
Author(s)Emma Andrus, Associate Editor
Click here to answer our poll.
Advertisement
The
The 5-day CME course offers lectures and insights from leading dermatology professionals amassing a range of specialties, topics, and professional interests.
Will you be attending? Let us know by answering our poll below.
If you are planning to attend, either as a registered attendee or as a lecturer, we want to hear from you.
Connect with our team by emailing us
Are you attending the 2024 Winter Clinical Dermatology Conference in Hawaii?
Advertisement
Related to this article
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
ORKA-001 Achieves 61% Complete Skin Clearance in Psoriasis
2
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
3
Avoiding Common Mistakes When Escalating Therapy in Psoriasis
4
FDA Revises TB Evaluation Guidance for SKYRIZI
5